Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Phio Pharmaceuticals Corp

PHIO
Current price
2.61 USD -0.26 USD (-9.06%)
Last closed 2.63 USD
ISIN US71880W3034
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 341 161 USD
Yield for 12 month -87.11 %
1Y
3Y
5Y
10Y
15Y
PHIO
21.11.2021 - 28.11.2021

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. Address: 11 Apex Drive, Marlborough, MA, United States, 01752

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

36 USD

P/E ratio

0.0119

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+30 000 USD

Current Year

-184 000 USD

Last Year

-193 000 USD

Current Quarter

-1 000 USD

Last Quarter

-34 000 USD

Key Figures PHIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -8 567 000 USD
Operating Margin TTM
PE Ratio 0.0119
Return On Assets TTM -61.07 %
PEG Ratio
Return On Equity TTM -126.86 %
Wall Street Target Price 36 USD
Revenue TTM
Book Value 7.4 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM -7 012 000 USD
Earnings per share 229.23 USD
Diluted Eps TTM 229.23 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics PHIO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History PHIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:9
Payout Ratio
Last Split Date 05.07.2024
Dividend Date 15.01.2020

Stock Valuation PHIO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 0.0119
Forward PE 0.3064
Enterprise Value Revenue 172.2001
Price Sales TTM 48.0082
Enterprise Value EBITDA 0.6124
Price Book MRQ 0.6205

Financials PHIO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators PHIO

For 52 weeks

2.4 USD 29.07 USD
50 Day MA 4.07 USD
Shares Short Prior Month 16 373
200 Day MA 6.32 USD
Short Ratio 0.24
Shares Short 17 573
Short Percent 2.05 %

Dynamics of changes in the value of assets

M

MXTLF

0.010 USD Metalex Ventures Ltd 0 (0%)
Detailed analytics
Z

ZRVT

0.030 USD Zurvita Holdings Inc 0 (0%)
Detailed analytics
B

BASA

0.0079 USD Basanite Inc 0 (0%)
Detailed analytics
J

JDNRF

0.040 USD Jayden Resources Inc. 0 (0%)
Detailed analytics
A

AKAN

1.10 USD Akanda Corp -0.03 (-2.6%)
Detailed analytics